Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Kacy Rogers

Nurse Practitioner Indianapolis, IN Nurse Practitioner

NPI 1164913703 CMS profile 10520664

8450 Northwest Blvd, Indianapolis, IN 46278

Open in the dashboard

General payments

$76,633

468 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kacy Rogers of Indianapolis, IN is reported in the CMS Open Payments database as having received $76,633 across 468 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34,110 130
2024 General $33,999 144
2023 General $6,066 77
2022 General $1,571 66
2021 General $888 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kacy Rogers
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Kacy Rogers were reported at $34,110. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Kacy Rogers Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $888 $135 $40–$426 $132
2022 $1,571 $152 $48–$470 $149
2023 $6,066 $166 $54–$529 $160
2024 $33,999 $173 $55–$556 $164
2025 $34,110 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $63,000 263 payments
  2. Alexion Pharmaceuticals, Inc. $7,554 40 payments
  3. Kyowa Kirin, Inc. $3,314 15 payments
  4. Radius Health, Inc. $1,262 85 payments
  5. Boston Scientific Corporation $294 11 payments
  6. Vertos Medical, Inc. $201 1 payment
  7. Arbor Pharmaceuticals, Inc. $160 14 payments
  8. Abbott Laboratories $148 1 payment
  9. ITI, Inc. $109 6 payments
  10. Lundbeck LLC $77 4 payments
  11. Other $515 28 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $54,950 63 payments
  2. Travel and Lodging $10,619 56 payments
  3. Food and Beverage $8,966 341 payments
  4. Consulting Fee $2,040 2 payments
  5. Education $57 6 payments
Products named General payments · program years 2021–2025
  1. EVENITY $61,481 253 payments
  2. Crysvita $3,294 14 payments
  3. STRENSIQ $2,206 24 payments
  4. Prolia $1,608 91 payments
  5. Tymlos Endocrinology $1,024 71 payments
  6. Superion Indirect Decompression System $270 9 payments
  7. mild Device Kit $201 1 payment
  8. Horizant $160 14 payments
  9. Tymlos Endocrinology $156 9 payments
  10. Proclaim IPG $148 1 payment
  11. Other $1,062 59 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

410

Median for Nurse Practitioner: 389

Drug cost

$1,009,469

Median for Nurse Practitioner: $21,885

Branded share of claims

64.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Forteo Teriparatide Brand 91 $391,589
Tymlos Abaloparatide Brand 129 $357,014
Teriparatide Generic 89 $229,221
Evenity (2 Syringes) Romosozumab-Aqqg Brand 12 $29,932
Ultra-Fine Short Pen Needle Pen Needle, Diabetic Brand 13 $728
Droplet Pen Needle Pen Needle, Diabetic Brand 19 $595
Alendronate Sodium Generic 57 $389

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$769,852

Of which drugs: $724,857

Medicare patients

277

Average age 74

Services billed

78,451

232 women, 45 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Osteoporosis 75%
Arthritis 70%
High blood pressure 65%
Depression 30%
Ischemic heart disease 24%
Diabetes 22%
Chronic kidney disease 21%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, romosozumab-aqqg, 1 mg J3111 Office 98 71,592 $609,269
Injection, denosumab, 1 mg J0897 Office 65 5,559 $115,588

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $30,968
$30,968 12 71,592
STRENSIQ
  • Alexion Pharmaceuticals, Inc. $1,931
$1,931 — —
Tymlos
  • Radius Health, Inc. $198
$198 129 —
Prolia
  • Amgen Inc. $101
$101 — 5,559
Crysvita
  • Kyowa Kirin, Inc. $36
$36 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

468 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record